Moderna shares double after experimental mRNA cancer treatment passes key test
Moderna shares surged more than double on Wednesday following positive results from a study of an experimental mRNA cancer treatment. The innovative therapy, called intismeran, is being co-developed by Moderna and Merck. Unlike traditional cancer vaccines, intismeran is tailored to each patient's unique tumor mutations. In ongoing trials, the combined treatment of intismeran with Merck's Keytruda immunotherapy showed significantly better outcomes compared to Keytruda alone in melanoma patients.
The experimental combination resulted in extended survival rates without cancer recurrence or metastasis.
Written by urgent.news from Gulf News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Promising Results for mRNA Cancer Vaccine from Moderna and Merck time.com
- Moderna and Merck shares soar on mRNA cancer vaccine axios.com
- Moderna, Merck breakthrough could usher in wave of cancer vaccines japantimes.co.jp
- How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer cbsnews.com
- Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck seekingalpha.com
